182 related articles for article (PubMed ID: 18823034)
1. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
2. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed?
Islam F; Nath N; Zehravi M; Khan J; Jashim SB; Charde MS; Chakole RD; Kumar KP; Babu AK; Nainu F; Khan SL; Rab SO; Emran TB; Wilairatana P
Nat Prod Bioprospect; 2023 Oct; 13(1):39. PubMed ID: 37843642
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.
Srour SA; Akin S
J Immunother Precis Oncol; 2023 Feb; 6(1):19-30. PubMed ID: 36751657
[TBL] [Abstract][Full Text] [Related]
5. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract][Full Text] [Related]
6. Size-based isolation and detection of renal carcinoma cells from whole blood.
De Alwis R; Hansson J; Lindgren D; Schoch S; Tejera A; Scholtz B; Elfving P; Möller C; Nilsson H; Johansson M; Axelson H
Mol Clin Oncol; 2022 May; 16(5):101. PubMed ID: 35463211
[TBL] [Abstract][Full Text] [Related]
7. Avelumab plus axitinib
Zhang Y; Wu S
Transl Cancer Res; 2019 Dec; 8(Suppl 6):S585-S588. PubMed ID: 35117136
[No Abstract] [Full Text] [Related]
8. Curcumin induces apoptosis and autophagy inhuman renal cell carcinoma cells via Akt/mTOR suppression.
Gong X; Jiang L; Li W; Liang Q; Li Z
Bioengineered; 2021 Dec; 12(1):5017-5027. PubMed ID: 34402718
[TBL] [Abstract][Full Text] [Related]
9. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
Xu Y; Miller CP; Warren EH; Tykodi SS
Hum Vaccin Immunother; 2021 Jul; 17(7):1882-1896. PubMed ID: 33667140
[TBL] [Abstract][Full Text] [Related]
10. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma.
Dasgupta P; Kulkarni P; Majid S; Hashimoto Y; Shiina M; Shahryari V; Bhat NS; Tabatabai L; Yamamura S; Saini S; Tanaka Y; Dahiya R
Cell Death Dis; 2020 Aug; 11(8):660. PubMed ID: 32814766
[TBL] [Abstract][Full Text] [Related]
11. The RNA-binding protein QKI suppresses tumorigenesis of clear cell renal cell carcinoma by regulating the expression of HIF-1α.
Shi F; Wei D; Zhu Z; Yan F; Wang F; Zhang K; Li X; Zheng Y; Yuan J; Lu Z; Yuan J
J Cancer; 2020; 11(6):1359-1370. PubMed ID: 32047543
[No Abstract] [Full Text] [Related]
12. The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma.
Garje R; An J; Greco A; Vaddepally RK; Zakharia Y
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31936065
[TBL] [Abstract][Full Text] [Related]
13. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts.
Werthmann PG; Kindermann L; Kienle GS
Complement Med Res; 2019; 26(4):276-279. PubMed ID: 30897582
[TBL] [Abstract][Full Text] [Related]
15. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract][Full Text] [Related]
16. Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment.
Garje R; An JJ; Sanchez K; Greco A; Stolwijk J; Devor E; Rustum Y; Zakharia Y
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513765
[TBL] [Abstract][Full Text] [Related]
17. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Oncogene; 2018 Aug; 37(34):4639-4661. PubMed ID: 29765155
[TBL] [Abstract][Full Text] [Related]
18. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors.
Small J; Washburn E; Millington K; Zhu J; Holder SL
Oncotarget; 2017 Nov; 8(56):95116-95134. PubMed ID: 29221116
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-720 Regulates E-cadherin-αE-catenin Complex and Promotes Renal Cell Carcinoma.
Bhat NS; Colden M; Dar AA; Saini S; Arora P; Shahryari V; Yamamura S; Tanaka Y; Kato T; Majid S; Dahiya R
Mol Cancer Ther; 2017 Dec; 16(12):2840-2848. PubMed ID: 28802251
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Shen J; Chen Z; Zhuang Q; Fan M; Ding T; Lu H; He X
PLoS One; 2016; 11(11):e0166482. PubMed ID: 27861542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
